Institutional Review Board

Institutional Review Board
Name	Institutional Review Board
Abbreviation	IRB
Formation	20th century
Purpose	Review of research involving human subjects
Region	International

Institutional Review Board is a committee established to review, approve, and monitor research involving human participants to ensure ethical standards and regulatory compliance. IRBs operate within universities, hospitals, pharmaceutical companies, and nonprofit research centers to protect participant welfare, balance risks and benefits, and uphold informed consent. The development and functioning of IRBs connect to landmark events, laws, institutions, and figures that shaped modern research ethics and oversight.

History

The modern IRB system emerged from responses to ethical crises and legal developments. Influential episodes such as the Nuremberg trials, the Tuskegee syphilis experiment, and the Willowbrook State School public controversies prompted national attention to protections for human subjects. Legislative and policy milestones including the Nuremberg Code, the Declaration of Helsinki, and the National Research Act informed institutional structures. Implementation at major institutions—National Institutes of Health, Food and Drug Administration, and large academic centers like Harvard University and Johns Hopkins University—translated international principles into domestic review mechanisms. Subsequent reports and inquiries by bodies such as the Belmont Report commission and panels at World Health Organization influenced expansion and harmonization across countries and organizations like the Council for International Organizations of Medical Sciences.

Purpose and Functions

IRBs serve to protect the rights, safety, and welfare of human subjects in research conducted or supported by institutions. Primary functions include risk–benefit assessment tied to provisions in statutes like the Common Rule and regulatory expectations of agencies such as the Food and Drug Administration and Department of Health and Human Services. IRBs review protocols from investigators at institutions including Mayo Clinic, Massachusetts General Hospital, Stanford University, and University of California, San Francisco to evaluate informed consent processes, confidentiality safeguards, and participant selection. They also monitor ongoing studies, review adverse events, and may suspend or terminate approval when noncompliance or unanticipated risks arise, reflecting practices codified by regulators such as the European Medicines Agency and guidance from Council of Europe instruments.

Composition and Membership

Regulations require IRBs to include diverse membership to represent varied perspectives on research proposals. Typical membership includes clinicians and scientists from fields represented by institutions like Columbia University, Yale University, University of Michigan, and community or lay representatives drawn from constituencies near facilities such as Cleveland Clinic and Kaiser Permanente. Federal and international guidance encourage inclusion of members with expertise in ethics, law, and specific populations—examples include specialists from American Medical Association, American Psychological Association, and advocates from organizations like National Institutes of Mental Health. Rules often require at least one member unaffiliated with the institution and at least one non-scientist, with rosters reflecting diverse disciplines including representatives linked to World Medical Association deliberations.

Regulatory Framework and Ethics Guidelines

IRB operations are governed by statutory regulations, agency rules, and ethical documents. In the United States, the Common Rule codified at multiple agencies, and FDA regulations govern drug and device trials. Foundational ethical guidance derives from the Declaration of Helsinki, the Nuremberg Code, and the Belmont Report which articulated principles of respect for persons, beneficence, and justice. International research involving entities such as World Health Organization, European Commission, and multinational sponsors like Pfizer and GlaxoSmithKline must navigate varying national regulations and harmonization efforts like those promoted by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Institutional policies at organizations such as University of Oxford, Karolinska Institutet, and National University of Singapore further interpret regulatory obligations.

Review Process and Procedures

The IRB review process typically begins with protocol submission by an investigator affiliated with institutions like University of Pennsylvania or Imperial College London. Initial screening determines whether a project qualifies for exempt, expedited, or full board review under criteria linked to the Common Rule or equivalent national statutes such as those enforced by the Health Research Authority in the United Kingdom. Reviews evaluate consent forms, recruitment materials, data management plans, and statistical methods often developed in collaboration with centers like Johns Hopkins Bloomberg School of Public Health or London School of Hygiene & Tropical Medicine. Meetings may include deliberation of adverse event reports, protocol amendments, and continuing review. Decisions—approval, conditional approval, deferral, or disapproval—are documented, and oversight continues through site monitoring, data safety monitoring boards associated with entities like National Cancer Institute, and audit trails maintained by institutional offices such as sponsored research offices.

Controversies and Criticisms

IRBs face criticism regarding variability, bureaucratic burden, conflicts of interest, and responsiveness. High-profile disputes at institutions including Duke University and University of California, Los Angeles have spotlighted tensions between rapid scientific advancement and participant protection. Scholars and policymakers affiliated with Kennedy Institute of Ethics, Berkman Klein Center, and think tanks such as The Hastings Center have debated centralization versus local review, transparency, and the capacity to assess multi-site trials for sponsors like Roche or Novartis. Allegations of inconsistent decisions across IRBs in cities like Boston, New York City, and Chicago prompted calls for reliance agreements and single IRB models promoted by National Institutes of Health policy. Ongoing discussions involve balancing participant protection with innovation in fields represented by MIT Media Lab, Broad Institute, and emerging technologies in genetics and artificial intelligence overseen by institutions like Allen Institute for AI.

Category:Research ethics